Challenges in Conducting Studies in Chronic Graft-versus-Host Disease
Peer review is under the responsibility of IACH
- 10.2991/chi.d.190314.001How to use a DOI?
- GvHD; GRFS; FFS; Response criteria; Composite endpoints
The lack of standardized criteria for measuring therapeutic response has been a major obstacle to the development of therapeutic trials in chronic graft-versus-host disease (cGvHD). Nevertheless, recent advances have been made in understanding of the biology and pathophysiology of cGvHD, as well as establishing more precise criteria for the diagnosis and classification of disease manifestations. The momentum has shifted, and currently there is a long list of new potential treatment targets being identified for cGvHD. Consequently, new drugs are being implemented for its prophylaxis and treatment. It is crucial to continue that trend and develop better systems to test new drugs in clinical practice that would eventually translate toward seeking regulatory review and approval. We provide a historical perspective and current challenges in conducting cGvHD clinical trials.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Iskra Pusic AU - Steven Z. Pavletic PY - 2019 DA - 2019/03/18 TI - Challenges in Conducting Studies in Chronic Graft-versus-Host Disease JO - Clinical Hematology International SP - 36 EP - 44 VL - 1 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.190314.001 DO - 10.2991/chi.d.190314.001 ID - Pusic2019 ER -